8-K: Kronos Bio Completes Acquisition by Concentra Biosciences, Shares Delisted from Nasdaq

Kronos Bio, Inc. has successfully completed its merger with Concentra Biosciences, LLC, becoming a wholly-owned subsidiary and leading to the delisting of its common stock from Nasdaq.

Summary

• Kronos Bio, Inc. (Kronos) has completed its previously announced merger with Concentra Biosciences, LLC (Concentra) through its subsidiary, Concentra Merger Sub IV, Inc.
• The tender offer for all outstanding shares of Kronos common stock expired on June 18, 2025, with 44,503,838 shares, or approximately 72.90% of outstanding shares, validly tendered and not withdrawn.
• The number of tendered shares satisfied the Minimum Tender Condition, and all other offer conditions were met.
• On June 20, 2025 (the Closing Date), Merger Sub merged into Kronos, with Kronos continuing as the surviving, wholly-owned subsidiary of Concentra.
• Each outstanding share of Kronos common stock (excluding treasury shares, shares owned by Parent/Merger Sub/subsidiaries, or shares exercising appraisal rights) was converted into the Offer Price.
• The Offer Price consists of $0.57 in cash per share (Cash Amount) plus one non-transferable contractual contingent value right (CVR) per share.
• In-the-money Company Stock Options were cancelled in exchange for cash (Cash Amount minus exercise price) and one CVR per underlying share.
• Company Stock Options with an exercise price equal to or greater than the Cash Amount were cancelled for no consideration.
• Vesting for all Company Restricted Stock Units was accelerated, and each RSU was cancelled in exchange for the Cash Amount and one CVR.
• Kronos has notified Nasdaq to suspend trading of its shares effective before the opening of trading on June 20, 2025, and to file Form 25 for delisting and deregistration.
• The Surviving Corporation intends to file Form 15 with the SEC to terminate registration under Section 12(g) and suspend reporting obligations under Section 13 and 15(d) of the Exchange Act.
• The company's certificate of incorporation and bylaws were amended and restated, authorizing 10,000 shares of Common Stock with a par value of $0.001.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company ceases to be publicly traded (a negative for public investors seeking liquidity), the successful completion of the acquisition provides a defined cash value and a contingent upside (CVR) to former shareholders. For the acquiring entity, it's a successful strategic move.

Positives

• The successful completion of the tender offer and merger provides liquidity and a contingent value right to former Kronos Bio shareholders.
• The acquisition allows Kronos Bio to continue its operations as a wholly-owned subsidiary, potentially benefiting from Concentra's resources and strategic direction.

Negatives

• Kronos Bio, Inc. common stock has been delisted from The Nasdaq Global Select Market, ending its public trading status.
• Shareholders will no longer hold publicly traded equity in Kronos Bio, losing direct market liquidity and voting rights.
• The contingent value right (CVR) is non-transferable, limiting its liquidity and making its value dependent on future events and Concentra's performance.

Risks

• The contingent value right (CVR) represents potential payments, meaning the ultimate value received by former shareholders beyond the cash amount is uncertain and contingent upon future events.
• The CVR is non-transferable, which means former shareholders cannot sell or trade their CVRs, limiting their ability to realize value until potential payments are made, if any.

Future Outlook

Following the completion of the merger, Kronos Bio, Inc. will operate as a wholly-owned subsidiary of Concentra Biosciences, LLC. The company's common stock will be delisted from Nasdaq, and it intends to terminate its SEC registration and suspend reporting obligations, transitioning from a public to a private entity. The future value for former shareholders holding CVRs is contingent on the terms and conditions of the CVR Agreement.

Management Comments

• The resignations of the former directors and officer were tendered in connection with the Merger and not as a result of any disagreements between the Company and the resigning individuals on any matters related to the Company's operations, policies, or practices.

Industry Context

This acquisition represents a consolidation event within the biotechnology or pharmaceutical sector, where larger entities or private equity firms acquire smaller, publicly traded companies. Such transactions often occur to integrate promising pipelines, achieve synergies, or take a company private to restructure or develop assets away from public market pressures. The use of a Contingent Value Right (CVR) is a common mechanism in biotech acquisitions, allowing the acquirer to tie a portion of the purchase price to the future success of specific drug candidates or milestones, thereby sharing risk with the acquired company's shareholders.

Comparison to Industry Standards

• The acquisition of a publicly traded biotech company via a tender offer followed by a short-form merger (pursuant to Section 251(h) of the DGCL) is a standard and efficient method for such transactions, particularly when a significant majority of shares are tendered.
• The inclusion of a Contingent Value Right (CVR) as part of the consideration is a common practice in the biotechnology and pharmaceutical industry, especially for companies with early-stage or unproven assets. This structure is similar to deals seen with companies like Celgene's acquisition of Receptos or Sanofi's acquisition of Principia Biopharma, where CVRs were used to bridge valuation gaps based on clinical trial outcomes or regulatory approvals.
• The offer price of $0.57 cash plus a CVR per share should be evaluated against the company's pre-announcement trading price and analyst valuations, though specific comparable companies or projects are not detailed in this filing. The 72.90% tender rate indicates strong shareholder acceptance of the offer terms, suggesting the offer was perceived as fair or attractive given the company's circumstances.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders (Former Public):** Received $0.57 cash per share and one non-transferable contingent value right (CVR) per share. Lost their equity ownership in a publicly traded company, along with associated voting rights and market liquidity. Those with in-the-money options and RSUs received cash and CVRs, while out-of-money options were cancelled for no consideration. Shareholders may exercise appraisal rights under Delaware law.
• **Employees (Former Kronos Bio):** Stock options and restricted stock units were accelerated and converted into cash and CVRs, providing a liquidity event for equity holders. New management team from Concentra Merger Sub IV, Inc. has taken over, potentially leading to changes in corporate culture or operational focus.
• **Management (Former Kronos Bio):** The entire board of directors and a key officer (Deborah Knobelman) resigned, replaced by Concentra's appointees. This signifies a complete change in leadership and strategic direction for the company.

Next Steps

• Filing of Form 25 by Nasdaq to effect delisting and deregistration of Shares under Section 12(b) of the Exchange Act.
• Filing of Form 15 by the Surviving Corporation with the SEC to terminate registration of Shares under Section 12(g) and suspend reporting obligations under Section 13 and 15(d) of the Exchange Act.
• Potential future payments to CVR holders based on the terms and conditions of the CVR Agreement.

Key Dates

Keywords

Kronos Bio, Concentra Biosciences, Merger, Acquisition, Tender Offer, Delisting, Contingent Value Right, CVR, Biotechnology, Pharmaceutical, Nasdaq, SEC Filing, Corporate Action